Update with CytoSorbents Corporation - Blood Purification Company Discusses Clinical Development and Business Update

CytoSorbents Corporation (NASDAQ: CTSO) is one of the leaders in critical care immunotherapy, specializing in blood purification, and its flagship product, CytoSorb® is approved in the European Union with distribution in 45 countries around the world, as an extracorporeal cytokine adsorber designed to reduce the “cytokine storm” or “cytokine release syndrome” that could otherwise cause massive inflammation, organ failure and death in common critical illnesses, according to the company’s website (see here: www.cytosorbents.com).

SNNLive caught up with Phillip P. Chan, MD, PhD, CEO of CytoSorbents Corporation at the BIO CEO & Investor Conference 2018 in New York City, NY, and they discuss the following topics:

- Overview and history of CytoSorbents Corporation

- Describes science of the company

- How CytoSorb® is different than what’s currently available

- Update on clinical development

- On working with the FDA

- Dr. Chan’s background

- Value catalysts

For more information about CytoSorbents Corporation, please visit: www.cytosorbents.com

The interview may contain forward-looking statements about CytoSorbents Corporation. See CytoSorbents Corporation's periodic filings with the Securities and Exchange Commission for more complete information.

Please read our full disclosure here.